Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.

Richard PhelpsJonathan A WinstonDaniel WynnMario HabekHans-Peter HartungEva Kubala HavrdováGlen S MarkowitzDavid H MargolinClaudio E RodriguezDarren P BakerAlasdair J Coles

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)

Close monitoring of alemtuzumab-treated MS patients facilitates diagnosis and treatment early in the nephropathy course when preservation of renal function is more likely.

Keyphrases

end stage renal disease
newly diagnosed
multiple sclerosis
ejection fraction
chronic kidney disease
mass spectrometry
prognostic factors
type diabetes
adipose tissue
patient reported outcomes
drug induced
weight loss
insulin resistance
glycemic control